Home » Other Drugs » Pfizer’s Inlyta (axitinib) approved by FDA

Pfizer’s Inlyta (axitinib) approved by FDA

Posted by on January 27, 2012 in Other Drugs, RCC News & Research - 1 Comment


blood vessels into tumorsThe FDA approved Pfizer’s Inlyta today, according to the Baltimore Sun. Inlyta, brand name for axitinib, is the latest drug to come to market for patients with advanced (metastatic) kidney cancer. Axitinib targets the vascular endothelial growth factor (VEGF) receptor, thereby helping to block the growth of blood vessels to feed the tumors. You can learn more about axitinib, and its results compared to Sorafenib (Nexavar) at Action to Cure Kidney Cancer.

  • http://www.facebook.com/layna.buskirk Layna Buskirk

    My father, diagnosed with stage 4 renal cell carcinoma in December 2005, has been on Sutent and IL-2 and now is going to start trying this drug this month, Inlyta/Axitinib. I hope it stops the growth of these tumors! That’s not too much to ask, right?! :) Good luck on your treatments, Chris.

© 2020 The Kidney Cancer Chronicles. All rights reserved. Icons by Komodo Media.